← Eichor
Study identifier: NCT05324748 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Repeated GON Injections in CCH

Condition: Cluster Headache  ·  Sponsor: Leiden University Medical Center

PhasePhase 3
Planned participants50
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

Background: \- The effect of repeated GON-injections has never been studied in a double-blind randomized trial as a prophylactic therapy in a well-documented group of chronic patients. As such, (repeated) GON-injection has not yet found its place in current (inter)national treatment protocols for chronic cluster headache. Objectives: \- The primary objective is to determine if repeated GON-injection result in effective control of cluster headache attacks for more days compared to placebo in chronic cluster headache. Eligibility: \- Patients will be selected from the LUMC (Leiden University Medical Center) and CWZ (Canisius Wilhelmina Hospital) chronic cluster headache populations, diagnosed based upon the ICHD-3. Design: \- Bi-centre, randomized, double-blind, placebo-controlled retention trial with a maximum follow-up of one year.

This description comes directly from the study's public registry record.

Talk to the study team

Willemijn Naber  ·  0715262587  ·  w.c.naber@lumc.nl

Always discuss trial participation with your own doctor first.

Locations (2)

Leiden University Medical CenterLeiden, NetherlandsRecruiting
Canisius Wilhelmina ZiekenhuisNijmegen, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05324748